Liver Transplant and Hepatobiliary Surgeon @ UCLA dedicated to the care of patients with end-stage liver disease and malignancies of the liver and bile ducts
Joined February 2020
- Tweets307
- Following599
- Followers1.1K
- Likes2.3K
Vatche G. Agopian retweeted
1/6 Published today in @HEP_Journal @docamitgs
ovid.com/10.1097/HEP.0000000…
➡️BEACON-HCC, a new treatment allocation system for #HCC, developed by @HCCLIVEConf consortium
AASLD Statement: aasld.org/hepatology-publish…
Vatche G. Agopian retweeted
The new BEACON-HCC treatment recommendations, presented by @docamitgs at @HCCLIVEConf today are outstanding 👏.
Really nicely incorporates best available evidence in 2026 re: locoregional treatments, systemic therapies & tumor biology. @OncoAlert
Vatche G. Agopian retweeted
👏Congrats to the incredible authors:
Helen S. Te, MD, FAASLD @UChicagoMed
Thomas D. Schiano, MD, FAASLD @MountSinaiNYC
@VatcheAgopianMD @UCLAHealth
Anthony J. Demetris, MD @UPMCnews
@PaulYKwo, MD, FAASLD @StanfordMed
Brendan Martin McGuire, MD, FAASLD @uabmedicine
Mark W. Russo, MD, MPH, FAASLD @AtriumHealth
@NaziaSelzner, MD, PhD @UofT
W. Kenneth Washburn, MD @OSUWexMed
Gerald Scott Winder, MD MSc FACLP @UMichHealth
Vatche G. Agopian retweeted
Now Online in @LTxJournal: New #AASLD and @AST_info Practice Guideline on Adult #LiverTransplantation: Diagnosis and Management of Graft-Related Complications
bit.ly/4lDDyJO
Transplant surgeon overload for our incredible American Surgical Association past president Dr Jim Economou. Humbled to be here. #AmerSurg25 @andrewcam @The__Liver @UCLASurgery
Vatche G. Agopian retweeted
Center-Level variations are associated with disparate waitlist mortality and probability of liver transplant in MELD 35 and greater patients by @VatcheAgopianMD and colleagues.
journals.lww.com/lt/abstract…
Vatche G. Agopian retweeted
Every year I feel so fortunate to be part of this #livercancer community with these amazing friends who are true leaders sharing a common goal! Amongst the beautiful chaos that is life, it’s important to find your passion and your people 🤍. That’s a wrap @HCCLIVEConf!!
Vatche G. Agopian retweeted
💥Highlights at #UCLAGI
🔹Comprehensive Liver Research Center
🔹 Interactions in gut maintain health
🔹 CA Institute for Immunology & Immunotherapy
🔹 Research fellow to faculty: Fostering success
🔹 New clinical faculty
🔹 Register for Mellinkoff Symp
👉 online.flippingbook.com/view…
Vatche G. Agopian retweeted
Dr. Dennis Slamon is a true hero! His groundbreaking scientific discoveries have saved millions of lives worldwide. His contributions continue to inspire and transform the fight against cancer. #HealthcareHero #CancerResearch
Vatche G. Agopian retweeted
ctDNA-based MRD & survival in resectable CRC
@NatureMedicine
doi.org/10.1038/s41591-024-0…
🔎CIRCULATE-🇯🇵 GALAXY, 2,240 pts
👉shorter DFS in MRD+ patients
👉Better outcome after sustained ctDNA clearance in response to ACT
🧐What else do we need to implement into clinical practice?
@myESMO
Vatche G. Agopian retweeted
Y90 RADSEG now #1 bridging treatment in US ahead of TACE, ablation and EBRT @JVIRmedia @allisonkwong @DanSzeMDPhD @SIRspecialists @cirsesociety @ASTSChimera @AASLDtweets @EASLnews @_ILTS_ @AST_info @ASTRO_org @ACRORadOnc @NorthwesternIR @NorthwesternMed
jvir.org/article/S1051-0443%…
Congratulations Rajat and team on this incredible work!
This Post is from an account that no longer exists. Learn more
Vatche G. Agopian retweeted
Had a fantastic time in Toronto for #ILCA2024 - full of learning and connections with some of my favorite people! A special shout out to @docamitgs for his leadership as chair of the planning committee @ILCAnews
Vatche G. Agopian retweeted
Just out on the @TheLancetOncol : our NeoHCC Study 🗞️
📈 Path response after neoadj ICI predicts for RFS in HCC
🔥 HR 0.26 for RFS improvement with MPR
📊 30% of MPR is not predicted by ORR using RECIST 1.1
🎯 90% regression is the best threshold for RFS
@DJPinato @ILCAnews
Presenting at #ILCA24 & published Online First:
Pathological response following neoadjuvant immune checkpoint inhibitors in patients with #hepatocellularcarcinoma: a cross-trial, patient-level analysis
#livercancer @A_DAlessioMD @DJPinato
thelancet.com/journals/lanon…
Vatche G. Agopian retweeted
Last week, I joined like-minded individuals passionate about liver research, ranging from translational to clinical studies, at the inaugural @UCLAHealth Comprehensive Liver Research Symposium. Already looking forward to next year!
Vatche G. Agopian retweeted
🍂 October is #LiverCancer awareness month -now that summer is over and you’re making your conference plans, add @HCCLIVEConf on your list. We have an amazing agenda/speaker list and doing some exciting pre-conference work!! @docamitgs @DrElkhoueiry @riadsalemIR @JulieHeimbach
Save the date: HCC-LIVE is heading to Austin, TX, on February 20-22, 2025! Registration is coming soon. #HCCLIVE @AnjanaPillaiMD @riadsalemIR @docamitgs @JulieHeimbach @DrElkhoueiry
Vatche G. Agopian retweeted
Dr. Ronald Busuttil, distinguished professor of surgery emeritus at the @dgsomucla, has been named a recipient of the 2024 Medawar Prize by The Transplantation Society. He was recognized for his work advancing knowledge of liver transplantation. Read more: ucla.in/4bJLW5C
Vatche G. Agopian retweeted
Registration open! @UCLAHealth faculty discuss prevalent liver diseases & their complications using a multi-disciplinary approach w/hepatologists, radiologists, addiction medicine & surgeons. #livertwitter
🔹CME
🔹Hybrid
👉 Registration & agenda ucla.cloud-cme.com/course/co…
Vatche G. Agopian retweeted
The Comprehensive Liver Research Center @UCLAHealth is a team of 65+ NIH-funded 🔬 & 🩺. Our mission is to understand every aspect of #MASLD as it relates to the diverse population of LA County. The center is led by @autophagie1 & @VatcheAgopianMD.
👉uclahealth.org/departments/m…
